Sidharth Tyagi, MD, PhD

Sidharth Tyagi, MD, PhD conducts research on the molecular and cellular mechanisms of pain, with a particular emphasis on voltage-gated sodium channels as therapeutic targets.

Before coming to Yale, Dr. Tyagi trained at the University of Colorado, where he investigated the role of voltage-gated calcium channels in ALS and other neurodegenerative diseases.

At Yale, he pursued PhD training with Stephen Waxman, MD, PhD, and has led projects defining sodium channel architecture in sensory neurons, the regulation of nociceptor excitability by inflammation, and the development of scalable tools for ion channel drug discovery, including high-throughput electrophysiology (Cell Reports Methods, Nature Protocols) and real-time imaging of membrane protein dynamics (Nature Protocols, cover article). His research has yielded more than 30 publications, including work in Cell Reports, PNAS, and Nature Reviews Neuroscience.

A principal outcome of his PhD research is UbiquiNav, a selective degrader of the Nav1.8 channel that reduces sensory neuron excitability and demonstrates analgesic efficacy in vivo. This project, supported by an NIH F31 fellowship, is the subject of a U.S. patent and ongoing translational development, bridging basic neuroscience and drug discovery.

Dr. Tyagi’s research integrates ion channel biology, high-throughput screening, and translational neuroscience to advance non-addictive pain therapeutics.